Meetings with Dominic LeBlanc reported by registered lobbyists. Lobbyists must report every oral, arranged meeting with an MP, minister or other designated public office holder.
← Dominic LeBlancEvery reported meeting
Newest first, back to November 2021 if Dominic LeBlanc held office then.
-
Reported by Jasmin Begagic · In-house (corporation)
- Dominic LeBlanc · President of the King's Privy Council for Canada and Minister of International Trade and Intergovernmental Affairs
Work with government to facilitate the process of selling goods and services online, and delivering them to consumers. Read more
Work with government to promote and support Canada’s digital economy, including ensuring the availability of a high-skilled tech workforce.
-
Reported by Véronique Proulx · In-house (organization)
- Dominic LeBlanc · Président du Conseil privé du Roi pour le Canada et Ministre du Commerce international et des Affaires intergouvernementales
- Miro Froehlich · Directeur des politiques, Privy Council Office (PCO)
Rencontres avec les ministres, les cabinets et les équipes d’Affaires mondiales Canada afin de porter les priorités de nos membres en matière de relations commerciales avec les États-Unis, de révision de l’ACEUM, de diversification des marchés d’exportation et d’exportations en défense. Read more
Rencontre avec le ministre et son cabinet afin de discuter des défis et opportunités des entreprises québécoises. Présentation de solution afin d’encourager le repreneuriat au Québec. Discussion sur les enjeux découlant des restrictions liées à l’immigration économique au Québec.
-
Reported by Lisa Baiton · In-house (organization)
- Dominic LeBlanc · President of the King’s Privy Council for Canada and Minister responsible for Canada-U.S. Trade, Intergovernmental Affairs, Internal Trade and One...
- Janice Charette · Chief Trade Negotiator to the United States, Privy Council Office (PCO)
Communicating with the Government of Canada about energy trade between the United States and Canada, including the construction and operation of prospective pipeline projects and the imposition of potential tariffs on oil and gas and the renegotiation of the Canada-United States-Mexico Agreement (“CUSMA”), formerly known as the North American Free Trade Agreement (“NAFTA”). Read more
-
Reported by Pierre Gratton · In-house (organization)
- Mélanie Joly · Minister of Industry and Minister responsible for Canada Economic Development for Quebec Regions, Innovation, Science and Economic Development Canada (ISED)
- Dominic LeBlanc · President of the King's Privy Council for Canada and Minister of International Trade and Intergovernmental Affairs
- Janice Charette · Chief Trade Negotiator to the United States, Privy Council Office, Privy Council Office (PCO)
Critical Minerals Strategy as it relates to the Government of Canada's policies and/or programs in support of critical mineral development
-
Reported by David Goodman · In-house (corporation)
- Dominic LeBlanc · Président du Conseil privé du Roi pour le Canada et Ministre du Commerce international et des Affaires intergouvernementales
Policies aimed at reinforcing pharmaceutical supply chain.
-
Reported by Meeral Tashfeen · Consultant
- Dominic LeBlanc · President of the King's Privy Council for Canada and Minister of International Trade and Intergovernmental Affairs
Arranging meetings to advocate for research and infrastructure support, and to increase awareness of the client's research capabilities.
-
Reported by Ken Seitz · In-house (corporation)
- Dominic LeBlanc · President of the King's Privy Council for Canada and Minister of International Trade and Intergovernmental Affairs, Privy Council Office (PCO)
Input regarding policies that enhance or impede the competitiveness of Canada's agriculture and fertilizer industries. Read more
Ensuring the ongoing reliability of the transportation supply chain.
-
Reported by Vittoria Bellissimo · In-house (organization)
- Dominic LeBlanc · President of the King's Privy Council for Canada and Minister of International Trade and Intergovernmental Affairs
- Galen Richardson · Director of Stakeholder Relations, Privy Council Office (PCO)
- Nasser Haidar · Senior Policy Advisor, Intergovernmental Affairs Secretariat (IGA)
The proposed consultation on a Domestic Content Requirement for the Clean Electricity and Clean Technology Investmet Tax Credit as put forward in Budget 2025. Read more
Advocating for policies that would encourage the development of a stronger domestic supply chain for the renewable energy and energy storage sectors.
Canada's Clean Economy Investment Tax Credits as put forward in Budget 2025.
-
Reported by Greg Ebel · In-house (corporation)
- Dominic LeBlanc · President of the King's Privy Council for Canada and Minister of International Trade and Intergovernmental Affairs
- Galen Richardson · Senior Advisor, Stakeholder Relations, Privy Council Office (PCO)
Discussions regarding climate policies and initiatives, including the federal carbon charge, the Clean Fuel Standard, methane regulations, and the output-based pricing system, as well as policy supports for innovations that reduce greenhouse gas emissions (including Renewable Natural Gas, Compressed Natural Gas, CCUS, hydrogen and power-to-gas). Read more
Discussions regarding policy developments on Indigenous engagement, consultation and economic inclusion.
Discussions regarding Canadian competitiveness, including on regulatory efficiency, as it pertains to environmental assessments and climate policies and taxation.
Discussions regarding market access for energy products, maintaining the integrated North American energy market, Canada-U.S. trade and cross-border issues and Canadian energy exports to other jurisdictions.
Discussions regarding projects, expansions, optimizations, and changes to tolling arrangements relating to Enbridge’s liquids pipelines, natural gas pipelines, and utilities and power assets.
-
Reported by Kate Mah · Consultant
- Dominic LeBlanc · President of the King's Privy Council for Canada and Minister of International Trade and Intergovernmental Affairs
- Galen Richardson · Senior Advisor, Stakeholder Relations, Privy Council Office (PCO)
Encourage the federal government to implement measures to promote interprovincial trade and the harmonization of regulations regarding maritime transportation between the provinces. Read more
Work with the federal government to promote stable trade relations and regulatory harmonization between Canada and the United States on the Great Lakes and St. Lawrence, including on the classification of vessels, ballast water regulations, and other measures impacting short-sea shipping over shared waters.
Working with Transport Canada and Global Affairs Canada to ensure that regulations around water treatments affecting operations of the Canadian fleets, who are sharing trade routes with USA fleets, are harmonized with the USA regulatory body to maintain Canada's competitive on the market.
-
Reported by Louis Martel · In-house (corporation)
- Dominic LeBlanc · Président du Conseil privé du Roi pour le Canada et Ministre du Commerce international et des Affaires intergouvernementales
- Galen Richardson · Conseiller(e) principale Rélations avec les parties prenantes, Privy Council Office (PCO)
Assurer une prise en compte et application efficace des mesures du Fonds pour la diversification des corridors commerciaux annoncé dans le Budget 2026 tels qu'appliquées au secteur maritime. Read more
Supporter le renouvellement et la mise en oeuvre de l'Accord entre le Canada, les États-Unis d'Amérique et les États-Unis du Mexique afin de favoriser une stabilisation des relations commerciales et une harmonisation réglementaire entre le Canada et les États-Unis, deux des principaux marchés du Groupe CSL.
-
Reported by Lisa Baiton · In-house (organization)
- Dominic LeBlanc · President of the Privy Council and Minister responsible for Canada-U.S. Trade, Intergovernmental Affairs, Internal Trade and One Canadian Economy
- Corey Hogan · Parliamentary Secretary to the Minister of Energy and Natural Resources
Communicating with the Government of Canada about the Output-Based Pricing System (“OBPS”), sometimes colloquially referred to as the industrial carbon tax, under the Greenhouse Gas Pollution Pricing Act, S.C. 2018, c. 12, s. 186, more specifically its impacts on the oil and gas sector. Read more
Communicating with the Government of Canada about its methane strategy, including its (draft) Oil and Gas Methane Regulations, more specifically those sections that relate to (i) a proposed methane emissions cap for the upstream oil and gas sector and (ii) a proposed international methane emission inventory.
Communicating with the Government of Canada about energy trade between the United States and Canada, including the construction and operation of prospective pipeline projects and the imposition of potential tariffs on oil and gas and the renegotiation of the Canada-United States-Mexico Agreement (“CUSMA”), formerly known as the North American Free Trade Agreement (“NAFTA”).
Communicating with the Government of Canada, in general, about opportunities and challenges facing the oil and gas sector in Canada, including as it relates to investor confidence, competitiveness and export market development. The goal of these communications is to increase investment in Canada.
Communicating with the Government of Canada, in general, about the impact of global geopolitical risks (including those related to Iran, Russia and Venezuela) on oil and gas prices, supply chains and markets.
-
Reported by Richard Kruger · In-house (corporation)
- Dominic LeBlanc · President of the King's Privy Council for Canada and Minister of International Trade and Intergovernmental Affairs, Privy Council Office (PCO)
- Galen Richardson · Senior Advisor, Stakeholder Relations, Privy Council Office (PCO)
- Nasser Haidar · Senior Policy Advisor, Intergovernmental Affairs Secretariat (IGA)
Discussions with government on the Impact Assessment process and impact assessments for energy projects. Read more
Discussions with government about federal climate policies such as the Emission Cap, the Clean Fuel Regulations, the Output Based Pricing System, and ZEV mandate.
Discussions with government on policy and fiscal supports, and regulatory challenges related to decarbonization, including projects like Pathways.
-
Reported by Tim Hollander · In-house (corporation)
- Dominic LeBlanc · President of the King's Privy Council for Canada and Minister of International Trade and Intergovernmental Affairs
- Galen Richardson · Senior Advisor, Stakeholder Relations, Privy Council Office (PCO)
- Janice Charette · Chief Trade Negotiator, Privy Council Office (PCO)
Discussions on North American trade.
-
Reported by Cyril Dimitris · In-house (corporation)
- Dominic LeBlanc · President of the King's Privy Council for Canada and Minister of International Trade and Intergovernmental Affairs
- Janice Charette · Chief Trade Negotiator to the United States, Global Affairs Canada (GAC)
- Galen Richardson · Senior Advisor, Stakeholder Relations, Privy Council Office (PCO)
Communication regarding trade related issues, including free trade agreements such as the Canada-US-Mexico Free Trade Agreement, as it relates to the auto industry. Read more
Communication and education regarding Toyota's business in Canada.
-
Reported by Raymond Chun · In-house (corporation)
- Dominic LeBlanc · President of the King's Privy Council for Canada and Minister of International Trade and Intergovernmental Affairs
Imposition of tariffs and renewal of Canada, US, Mexico trade agreement
-
Reported by Iain Graham · In-house (organization)
- Karim Bardeesy · Member of Parliament
- Dominic LeBlanc · President of the King's Privy Council for Canada and Minister of International Trade and Intergovernmental Affairs
- Marjorie Michel · Minister of Health, Health Canada (HC)
- Martin Moen · Deputy Minister, Trade Policy and Negotiations, Global Affairs Canada (GAC)
and 7 moreShow fewer
- Manuela Tomic · Senior Policy Advisor, Innovation, Science and Economic Development Canada (ISED)
- Janice Charette · Chief Trade Negotiator to the United States, Privy Council Office (PCO)
- Nasser Haidar · Senior Policy Advisor, Intergovernmental Affairs Secretariat (IGA)
- Ritu Banerjee · Assistant Deputy Minister, Innovation, Science and Economic Development Canada (ISED)
- Shalene Curtis-Micallef · Deputy Minister, Health, Health Canada (HC)
- Justine Frame · Special Assistant, Policy, Health Canada (HC)
- Sandenga Yeba · Director of Policy & Deputy Chief of Staff, Health Canada (HC)
Free trade agreements as they relate to the biopharmaceutical industry. Read more
Communication around existing drug shortages and shared solutions to mitigate the impact on Canadians.
-
Reported by Laetitia Decroix Guilloux · In-house (corporation)
- Dominic LeBlanc · President of the King's Privy Council for Canada and Minister of International Trade and Intergovernmental Affairs, Privy Council Office (PCO)
- Karim Bardeesy · Parliamentary Secretary to the Minister of Industry, Innovation, Science and Economic Development Canada (ISED)
- Marjorie Michel · Minister, Health Canada (HC)
- Nasser Haidar · Senior Policy Advisor, Privy Council Office (PCO)
and 7 moreShow fewer
- Janice Charette · Chief Trade Negotiator to the United States, Privy Council Office (PCO)
- Martin Moen · Associate Assistant Deputy Minister, Trade Policy and Negotiations, Global Affairs Canada (GAC)
- Ritu Banerjee · Assistant Deputy Minister, Innovation, Science and Economic Development Canada (ISED)
- Manuela Tomic · Senior Policy Advisor, Office of the Minister of Industry, Innovation, Science and Economic Development Canada (ISED)
- Justine Frame · Policy Advisor, Minister’s Office, Health Canada (HC)
- Sandenga Yeba · Deputy Chief of Staff and Director of Policy to the Minister, Health Canada (HC)
- Shalene Curtis-Micallef · Deputy Minister, Health Canada (HC)
Canadian Drug Agency: the mandate and creation of a new Canadian Drug Agency and transition work to support pharmacare-related initiatives, including patient access and reimbursement framework. Read more
Canada-United States-Mexico Agreement (CUSMA) and pharmaceutical intellectual property protection.
Incentives and programs to attract and support manufacturing activities in Canada
Development of Health Emergency Readiness Canada agency, and role in promoting development life sciences sector.
-
Reported by An Van Gerven · In-house (corporation)
- Dominic LeBlanc · President of the King's Privy Council for Canada and Minister of International Trade and Intergovernmental Affairs
- Karim Bardeesy · Member of Parliament
- Marjorie Michel · Ministre de la Sante, Health Canada (HC)
- Janice Charette · Chief Trade Negotiator, Global Affairs Canada (GAC)
and 7 moreShow fewer
- Manuela Tomic · Senior Policy Advisor, Innovation, Science and Economic Development Canada (ISED)
- Ritu Banerjee · Assistant Deputy Minister, Innovation, Science and Economic Development Canada (ISED)
- Nasser Haidar · Senior Policy Advisor, Intergovernmental Affairs Secretariat (IGA)
- Martin Moen · Associate Assistant Deputy Minister of the International Trade Branch, Global Affairs Canada (GAC)
- Justine Frame · Special Assistant - Policy, Health Canada (HC)
- Sandenga Yeba · Director of Policy & Deputy Chief of Staff, Health Canada (HC)
- Sharlene Curtis-Micallef · Deputy Minister, Health Canada (HC)
Consider amendments to the Food and Drugs Act, or the Export and Imports Permits Act (Export Control List) or any other legislative and regulatory means in order to protect the Canadian supply of drugs in light of potential importation legislation in the United States. Read more
Advocacy as it relates to the Government of Canada potential responses to the US Administration Most Favored Nation drug pricing policy
Advocacy related to the federal government consultation on the review of the Canada US Mexico Trade Agreement
Engage the Federal Government on Health Canada’s Regulatory Innovation Agenda (Agile Licensing Modernization) to discuss opportunities for further harmonization; flexibility and predictability in the new regulatory framework being develop and its linkage to pillar 5 of the Biomanufacturing and Life Sciences Strategy.
The Department of Innovation, Science and Economic Development and the Innovation Agenda for the life sciences sector: policy or program initiatives to support life science research and development conducted in Canada and manufacturing capability.
Monitoring and engaging the Government and Parliamentarians on policies and programs related to Canada's life sciences & biomanufacturing strategy
Advocacy related to the new Buy Canada policy and the implications of including goods and services related to healthcare delivery, medical treatment, in particular drugs, vaccines and biologicals.
Advocacy with respect to Canada's proposed Countermeasures in Response to United States Tariffs on Canadian goods
-
Reported by Ugur Gunaydin · In-house (corporation)
- Dominic LeBlanc · President of the King’s Privy Council, Minister responsible for Canada-U.S. Trade, Internal Trade, Intergovernmental Affairs and One Canadian Economy, Privy Council Office (PCO)
- Karim Bardeesy · Parliamentary Secretary to the Minister of Industry, Innovation, Science and Economic Development Canada (ISED)
- Marjorie Michel · Minister, Health Canada (HC)
- Janice Charette · Chief Trade Negotiator to the United States, Privy Council Office (PCO)
and 7 moreShow fewer
- Ritu Banerjee · Assistant Deputy Minister, Innovation, Science and Economic Development Canada (ISED)
- Martin Moen · Associate Assistant Deputy Minister, Trade Policy and Negotiations, Global Affairs Canada (GAC)
- Manuela Tomic · Senior Policy Advisor to the Minister of Industry, Innovation, Science and Economic Development Canada (ISED)
- Nasser Haidar · Senior Policy Advisor, Privy Council Office (PCO)
- Sandenga Yeba · Deputy Chief of Staff & Director of Policy to the Minister, Health Canada (HC)
- Justine Frame · Policy Advisor, Minister's Office, Health Canada (HC)
- Shalene Curtis-Micallef · Deputy Minister, Health Canada (HC)
Communicating with government officials about international trade agreements, including the Canada-United States-Mexico Agreement (CUSMA), formerly known as the North American Free Trade Agreement (NAFTA), more specifically as it relates to trade in the life sciences and biopharmaceutical sectors. Read more
-
Reported by Mathilde Merlet · In-house (corporation)
- Dominic LeBlanc · President of the King's Privy Council for Canada and Minister of International Trade and Intergovernmental Affairs
- Karim Bardeesy · Member of Parliament
- Marjorie Michel · Minister of Health, Health Canada (HC)
- Janice Charette · Chief Trade Negotiator, Global Affairs Canada (GAC)
and 7 moreShow fewer
- Ritu Banerjee · Assistant Deputy Minister, Innovation, Science and Economic Development Canada (ISED)
- Martin Moen · Associate Assistant Deputy Minister for International Trade, Global Affairs Canada (GAC)
- Manuela Tomic · Senior Policy Advisor, Innovation, Science and Economic Development Canada (ISED)
- Nasser Haidar · Senior Policy Advisor, Intergovernmental Affairs Secretariat (IGA)
- Sandenga Yeba · Director of Policy & Deputy Chief of Staff, Health Canada (HC)
- Justine Frame · Policy Advisor, Health Canada (HC)
- Shalene Curtis-Micallef · Deputy Minister, Health Canada (HC)
The government's economic, health, investment, science and technology, and trade policies as they relate to the pharmaceutical industry
-
Reported by Wendy Zatylny · In-house (organization)
- Dominic LeBlanc · President of the King's Privy Council for Canada and Minister of International Trade and Intergovernmental Affairs
- Marjorie Michel · Minister of Health
- Karim Bardeesy · Member of Parliament
- Janice Charette · Chief Trade Negotiator to the United States, House of Commons
and 7 moreShow fewer
- Ritu Banarjee · Assistant deputy Minister, Innovation, Science and Economic Development Canada (ISED)
- Martin Moen · Assistant Associate Deputy Minister, Global Affairs Canada (GAC)
- Manuela Tomic · Senior Policy Advisor, Innovation, Science and Economic Development Canada (ISED)
- Nasser Haidar · Senior Policy Advisor, Intergovernmental Affairs Secretariat (IGA)
- Sandenga Yeba · Director of Policy & Deputy Chief of Staff, Health Canada (HC)
- Justine Frame · Policy Advisor, Health Canada (HC)
- Shalene Curtis-Micallef · Deputy Minister of Health, Health Canada (HC)
PATENTED MEDECINES PRICES REVIEW BOARD (PMPRB) PRICE REVIEW to ensure new guidelines and directives do not create disincentives for the introduction of new treatments in Canada Read more
INTELLECTUAL PROPERTY/PATENT POLICY AND REGULATIONS in respect of creating Canada as one of the world's most competitive jurisdictions in protecting IP (e.g., match level of European Union via CETA negotiations)
-
Reported by Bettina Hamelin · In-house (organization)
- Karim Bardeesy · Member of Parliament
- Dominic LeBlanc · President of the King's Privy Council for Canada and Minister of International Trade and Intergovernmental Affairs and One Canadian Economy, Privy Council Office (PCO)
- Marjorie Michel · Minister of Health, Health Canada (HC)
- Janice Charette · Chief Trade Negotiator to the United States, Privy Council Office (PCO)
and 7 moreShow fewer
- Ritu Banerjee · Assistant Deputy Minister, Health Emergency Readiness Canada, Innovation, Science and Economic Development Canada (ISED)
- Martin Moen · Assistant Associate Deputy Minister, Trade Policy and Negotiations, Global Affairs Canada (GAC)
- Manuela Tomic · Senior Policy Advisor, Innovation, Science and Economic Development Canada (ISED)
- Nasser Haidar · Senior Policy Advisor, Intergovernmental Affairs Secretariat (IGA)
- Sandenga Yeba · Deputy Chief of Staff and Director of Policy to the Minister of Health, Health Canada (HC)
- Justine Frame · Policy Advisor, Office of the Minister of Health, Health Canada (HC)
- Shalene Curtis-Micallef · Deputy Minister, Health, Health Canada (HC)
Policy measures to ensure security of drug supply in Canada and preserve Canada's attractiveness for biopharmaceutical launches, including in response to foreign pricing regulations Read more
Free trade agreements as they relate to the biopharmaceutical industry
-
Reported by David D. Jones · In-house (corporation)
- Dominic LeBlanc · President of the King's Privy Council for Canada and Minister of International Trade and Intergovernmental Affairs
- Karim Bardeesy · Member of Parliament
- Marjorie Michel · Minister of Health, Health Canada (HC)
- Janice Charette · Chief Trade Negotiator to the United States, Privy Council Office (PCO)
and 7 moreShow fewer
- Ritu Banerjee · Assistant Deputy Minister, Innovation, Science and Economic Development Canada (ISED)
- Martin Moen · Associate Asst Dep. Minister, Trade Policy and Negotiations, Global Affairs Canada (GAC)
- Manuela Tomic · Senior Policy Advisor, Innovation, Science and Economic Development Canada (ISED)
- Nasser Haidar · Senior Policy Advisor, Intergovernmental Affairs Secretariat (IGA)
- Sandenga Yeba · Director of Policy & Deputy Chief of Staff, Health Canada (HC)
- Justine Frame · Special Assistant- Policy, Health Canada (HC)
- Shalene Curtis-Micallef · Deputy Minister, Health Canada (HC)
National Pharmaceutical Strategy as it relates to the federal government's involvement in federal/provincial access to medicines framework. Read more
Canada's Access to Medicines Regime with respect to ensuring that the program allows for the delivery of timely access to needed medicines to the developing world supported by a business climate in Canada that continues to encourage research into further treatment and prevention of disease.
Pharmaceutical pricing policy issues arising from the jurisdiction of the Patended Medicines Prices Review Board (PMPRB) and R&D reporting.
Establish accountability with the federally financed Canadian Agency for Drugs and Technologies in Health (CADTH).
US - Canada Regulatory Cooperation Council (RCC) as it relates to the regulation of biopharmaceutical products.
Patented Medicines (Notice of Compliance) Regulations with respect to ensuring that patent rights are respected and are internationally competitive.
Food and Drug Regulations as it relates to data protection and the regulation and protection of biopharmaceutical products.
Patented Medicines Regulations as it relates to the regulation and protection of biopharmaceutical products.
Annual federal Budgets and Budget updates as it relates to the biopharmaceutical industry, and related updates and to Federal budgetary policy.
Food and Drugs Act and Regulations and the Import and Export Permits Act with respect to cross-border trade as it relates to the export of Canadian biopharmaceuticals.
-
Reported by Brigitte Nolet · In-house (corporation)
- Dominic LeBlanc · President of the King's Privy Council for Canada and Minister of International Trade and Intergovernmental Affairs
- Marjorie Michel · Minister of Health
- Karim Bardeesy · Member of Parliament
- Janice Charette · Chief Trade Negotiator to the United States, House of Commons
and 7 moreShow fewer
- Ritu Banerjee · Assistant Deputy Minister, Innovation, Science and Economic Development Canada (ISED)
- Martin Moen · Assistant Associate Deputy Minister, Trade Policy and Negotiations, Global Affairs Canada, Global Affairs Canada (GAC)
- Manuela Tomic · Senior Policy Advisor, Innovation, Science and Economic Development Canada (ISED)
- Nasser Haidar · Senior Policy Advisor, Intergovernmental Affairs Secretariat (IGA)
- Sandenga Yeba · Director of Policy & Deputy Chief of Staff, Health Canada (HC)
- Justine Frame · Special Assistant, Policy, Health Canada (HC)
- Shalene Curtis-Micallef · Deputy Minister, Health, Health Canada (HC)
Monitoring and engaging the Government and Parliamentarians on policies and programs that would provide greater clarity and predictability in the tax outcomes and improvements to tax measures such as the Manufacturing & Processing (M&P) credit and the Scientific Research & Developmental (SR&ED). Read more
From the Office of the Commissioner of Lobbying's open data, published November 5, 2026. Reports cover oral, arranged meetings with designated public office holders since November 22, 2021; lobbyists file them by the 15th of the following month. Names of MPs are matched to the current House of Commons, and bills are linked when the lobbyist's own description makes clear which bill it means. Contains information licensed under the Open Data Licence Agreement — Office of the Commissioner of Lobbying. Licence. PolitiKit is independent and is not endorsed by the Commissioner of Lobbying.